Kamada (NASDAQ: KMDA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Risk and Volatility

Kamada has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -3.79, indicating that its stock price is 479% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Kamada and Syros Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada 0 0 2 0 3.00
Syros Pharmaceuticals 0 0 6 0 3.00

Kamada currently has a consensus target price of $8.50, suggesting a potential upside of 78.01%. Syros Pharmaceuticals has a consensus target price of $26.37, suggesting a potential upside of 59.03%. Given Kamada’s higher possible upside, research analysts clearly believe Kamada is more favorable than Syros Pharmaceuticals.

Earnings and Valuation

This table compares Kamada and Syros Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Kamada $87.83 million 2.03 $1.94 million ($0.06) -79.57
Syros Pharmaceuticals $1.42 million 306.61 -$48.99 million ($2.13) -7.78

Kamada has higher revenue and earnings than Syros Pharmaceuticals. Kamada is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kamada and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kamada -2.24% -2.94% -2.03%
Syros Pharmaceuticals N/A -60.15% -54.25%

Insider & Institutional Ownership

7.3% of Kamada shares are owned by institutional investors. Comparatively, 59.6% of Syros Pharmaceuticals shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Kamada beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.